Clinical trials: Type 2 Diabetes Mellitus 1
Diabetes, Diabetes Mellitus, Type 1
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00698269
- Testing
- insulin detemir, biphasic insulin aspart 30, insulin aspart
- Where
- Saudi Arabia
- Volunteers
- 5,926 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
Blood Glucose Differences Using CGMs Between the Left and Right Arm in Patients With Diabetes
There are multiple CGMs that are FDA approved. However, there are few studies looking at the variability of measurements between the left and right arm, and none looking at this effect in diabetic patients.
- Trial name
- NCT05849428
- Testing
- Freestyle Libre 3
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of the Pacific
Diabetes, Diabetes Mellitus, Type 1
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01524809
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
The BRIGHT Study (Device Name: HALO System)
The purpose of the BRIGHT study is to evaluate safety and performance of the HALO SYSTEM in subjects with diabetes mellitus. The primary objectives of this clinical investigation are 1) the evaluation of sensor's performance by…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Diabetes Mellitus, Ketoacidosis, Diabetic
- Trial name
- NCT07745998
- Testing
- The HALO System
- Volunteers
- 12 people
- Sponsor
- Indigo Diabetes NV
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05644730
- Testing
- Fusion closed loop glucose control system
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ideal Medical Technologies
Type 2 Diabetes Mellitus
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single…
- Trial name
- NCT00989079
- Testing
- Ertugliflozin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients
The aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on intraocular pressure and anterior chamber parameters in patients with Diabetes Mellitus.
- Trial name
- NCT04932213
- Testing
- Tropicamide Ophthalmic
- Where
- Iran
- Volunteers
- 98 people
- Sponsor
- Semnan University of Medical Sciences
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be…
- Trial name
- NCT02806960
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
The addition of Biochaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to a facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02029924
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Adocia
Heart Failure, Type 2 Diabetes Mellitus
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and…
- Trial name
- Protocol1 (NCT03560323)
- Testing
- Beta-hydroxy-butyrate
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes.
- Trial name
- NCT07228117
- Testing
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 389 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2
The purpose of the study is to compare two closed-loop strategies in terms of glycemic control in Type 1 Diabetes during a camp setting. The proposed study is a four-segment feasibility study.
- Trial name
- NCT02776696
- Testing
- Advanced Hybrid Closed Loop System, Hybrid Closed Loop System
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Diagnosis and Physiopathology of Insulin Allergy
Insulin allergy (IA) is still observed even with recombinant human insulin and insulin analogs. Obviously, the usual attitude facing an allergy, i. e.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypersensitivity, Immediate Hypersensitivity
- Trial name
- Allerdiab (NCT01407640)
- Testing
- Allergy tests
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07803809
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 1 Diabetes
Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes
The purpose of the study is to examine whether a simplified meal approach (as compared to exact carbohydrate counting) can alleviate the need of carbohydrate counting without worsening postprandial control in youth and young…
- Trial name
- SMASH (NCT05481034)
- Testing
- SMA bolus option, Exactly estimated carbohydrate content bolus option
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- Lia Bally
Type 1 Diabetes Mellitus
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a type of medicine that help the kidneys get rid of extra sugar in the blood through urine.
- Trial name
- KETO-TRACK (NCT07225465)
- Testing
- FORXIGA
- Where
- 4 sites in Australia
- Volunteers
- 115 people
- Sponsor
- St Vincent's Hospital Melbourne
Type 1 Diabetes, Type 2 Diabetes
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port
This study investigated wearability and usability of the I-PORT™ Injection Port (I-PORT™), a new disposable injection port through which prescribed medication is injected subcutaneously from a standard syringe or pen.
- Trial name
- NCT00486109
- Testing
- I-Port(TM) Injection Port
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Patton Medical Devices
Diabetes Mellitus, Metabolic Integrity
Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes
The purpose of this study is to determine if restoring normal metabolic function in patients with type 1 or type 2 diabetes can improve the impact of the consequences of diabetic complications on the overall health and quality of…
- Trial name
- NCT01023165
- Testing
- Humulin, Humalog, Novolog
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Global Infusion and Aspiration Systems, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.